EUVIMEDEUVIMED entdecken
Crossref

Development of an adenosine deaminase-resistant cordycepin prodrug activated by Pseudomonas carboxypeptidase G2

Zhang Chen, Haiyang Yan, Houshi Ma, Liang Gao, Gangyin Luo, Li Li, Linlin Lu, Wenfei Dong, Lixing Zhang

Bioorganic Chemistry · 2025-07 · 162 · 108596

DOI: 10.1016/j.bioorg.2025.108596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025-07. Verfasst von Zhang Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomaterials and Stem Cells, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou 215163, Chin…. Hauptthemen laut MEDLINE: Prodrugs, Deoxyadenosines, Adenosine Deaminase, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Suzhou, Jiangsu Province People's Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cordycepin, also known as 3'-deoxyadenosine, is a bioactive natural antibiotic with numerous pharmacological properties including anticancer activity. Unfortunately, cordycepin is rapidly deaminated by adenosine deaminase (ADA) in vivo, which leads to the inactivation of this potent natural compound. In the present study, an ADA-resistant cordycepin prodrug (2) with the 6-NH2 masked by a glutamate-based protecting group was developed. Additionally, this cordycepin prodrug exhibited stability in serum-containing media. The prodrug is non-toxic in its standalone form, and the release of cordycepin occurs in the presence of Pseudomonas carboxypeptidase G2 (CPG2), rendering it appropriate for directed enzyme prodrug therapy. The concurrent application of CPG2 and prodrug significantly reduced the proliferation of 4T1 and U251 cancer cells, promoted apoptosis, and impeded the colony formation of 4T1 cells. Subsequent assessments utilizing the patient-derived breast cancer organoid model have demonstrated notable anticancer efficacy. The development of this prodrug presents a promising strategy to mitigate the inactivation of cordycepin in cancer therapy and minimizing toxicity to healthy cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsDeoxyadenosinesAdenosine DeaminaseAntineoplastic Agentsgamma-Glutamyl HydrolasePseudomonasHumansCell ProliferationAnimalsMiceMolecular StructureDrug Screening Assays, AntitumorStructure-Activity RelationshipDose-Response Relationship, DrugApoptosisCell Line, Tumor

Stichwörter der Autor:innen

Anticancer therapyCarboxypeptidase G2CordycepinProdrug

Substanzen

ProdrugsDeoxyadenosinescordycepinAdenosine DeaminaseAntineoplastic Agentsgamma-Glutamyl Hydrolase

Autor:innen und Institutionen

  • Department of Biomaterials and Stem Cells, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou 215163, China.
  • Engineering Equipment Integration Research Laboratory, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou 215163, China.
  • Center of Reproduction and Genetics, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou 215002, PR China.
  • The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. Electronic address: lulinlin000000@163.com.
  • Department of Biomaterials and Stem Cells, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou 215163, China. Electronic address: wenfeidong@sibet.ac.cn.
  • Department of Biomaterials and Stem Cells, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou 215163, China. Electronic address: zhanglx@sibet.ac.cn.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Program of Suzhou
  • Jiangsu Province People's Government
  • Ministry of Science and Technology of the People's Republic of China
  • National Key Research and Development Program of China

Zitieren

APA

Chen, Z., Yan, H., Ma, H., Gao, L., Luo, G., Li, L., Lu, L., Dong, W., & Zhang, L. (2025). Development of an adenosine deaminase-resistant cordycepin prodrug activated by Pseudomonas carboxypeptidase G2. Bioorganic Chemistry, 162, 108596. https://doi.org/10.1016/j.bioorg.2025.108596

Vancouver

Chen Z, Yan H, Ma H, Gao L, Luo G, Li L, et al. Development of an adenosine deaminase-resistant cordycepin prodrug activated by Pseudomonas carboxypeptidase G2. Bioorganic Chemistry. 2025;162:108596. doi:10.1016/j.bioorg.2025.108596

BibTeX
@article{Chen2025,
  author = {Chen, Zhang and Yan, Haiyang and Ma, Houshi and Gao, Liang and Luo, Gangyin and Li, Li and Lu, Linlin and Dong, Wenfei and Zhang, Lixing},
  title = {Development of an adenosine deaminase-resistant cordycepin prodrug activated by Pseudomonas carboxypeptidase G2},
  journal = {Bioorganic Chemistry},
  year = {2025},
  volume = {162},
  pages = {108596},
  doi = {10.1016/j.bioorg.2025.108596}
}
Kostenlos starten →